The upgraded NHS App, due to be ready in March, will allow almost all patients to contact their GP or hospital for non-urgent ...

Alex Brenchat, PhD, is VP and practice area lead for local pharmacovigilance services at PharmaLex. Brenchat has more than 20 ...

Novo Nordisk has filed another Citizen's Petition with the FDA seeking to block compounding pharmacies in the US from making ...

Every new drug entering clinical trials requires careful decision-making, particularly regarding trial design and resource ...

That is more than three times higher than last year, but not quite at the same level that was reached in the 2022-2023 flu season, according to the UK Health Security Agency (UKHSA), which has called ...

In a statement, Neumora revealed that the KOASTAL-1 study missed its primary endpoint, with navacaprant failing to achieve a ...

In a deal valued at up to $1 billion, Roche has licensed rights to a DLL3-directed antibody-drug conjugate (ADC) from China's ...

Capricor Therapeutics has completed its US marketing application for deramiocel, a cell therapy the US biotech hopes will ...

This tiered approach allows investors to engage at the level they’re most comfortable with, sparking their interest with a ...

The JV was set up in 2001 and has become increasingly peripheral to Hutchmed's core business of developing novel therapies ...

Now, Novartis hopes to be able to share the data with regulatory authorities in 2025, including the US FDA, in the hope of ...

Regeneron has bought Oxular, a UK-based specialist in retinal diseases, in a move that bolsters its already strong position ...